Nakamura M, Tsunoda S, Watabe Y, Shimomura T, Sakaki T, Konishi N, Hiasa Y
Department of Neurosurgery, Nara Medical University, Kashihara, Japan.
No To Shinkei. 1990 Oct;42(10):965-70.
The activity of glutathione S-transferase placental form (GST-pi) was examined in 100 cases including various histologic subtypes and grading of human brain tumors and 10 cases of fetal brains by immunohistochemical studies. The 69% of cases with brain tumors were shown to be positive for GST-pi. This activity in neuroepithelial tumors tended to increase in order to tumor grading, however, medulloblastoma and primitive neuroectodermal tumor (PNET) were not immunoreactive with GST-pi. Embryonal carcinoma showed strong staining, although fetal brains were negative. The metastatic brain tumors showed the same reactivity with GST-pi as those of original carcinomas. Moreover, the difference of GST-pi activity was investigated on some brain tumors treated with or without antitumor drug, such as 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU). The 85% of recurrent cases showed strong staining with GST-pi, and GST-pi activity seemed to be increased after treated with ACNU. The present study indicated that GST-pi might be a useful marker for human brain tumor, as the same conclusion was applicable to other neoplastic lesions examined previously. It is suggested that the increased GST-pi activity with malignancy of tumor may indicate the tendency to recurrence. The presence of such activity in tumor cells may also imply their acquired multidrug resistance. Our findings suggest that the evaluation of GST-pi activity in brain tumors will offer a predictive value for eventual behavior of the tumor.
通过免疫组织化学研究,检测了100例包括各种组织学亚型和分级的人脑肿瘤以及10例胎儿脑内谷胱甘肽S-转移酶胎盘型(GST-pi)的活性。69%的脑肿瘤病例显示GST-pi呈阳性。神经上皮肿瘤中的这种活性倾向于随着肿瘤分级增加,然而,髓母细胞瘤和原始神经外胚层肿瘤(PNET)对GST-pi无免疫反应。胚胎癌显示强染色,而胎儿脑呈阴性。转移性脑肿瘤与原发癌对GST-pi表现出相同的反应性。此外,还研究了一些接受或未接受抗肿瘤药物(如盐酸1-(4-氨基-2-甲基-5-嘧啶基)甲基-3-(2-氯乙基)-3-亚硝基脲(ACNU))治疗的脑肿瘤中GST-pi活性的差异。85%的复发病例显示GST-pi强染色,且用ACNU治疗后GST-pi活性似乎增加。本研究表明,GST-pi可能是人脑肿瘤的一个有用标志物,因为同样的结论适用于先前检查的其他肿瘤性病变。提示肿瘤恶性程度增加时GST-pi活性升高可能预示复发倾向。肿瘤细胞中这种活性的存在也可能意味着它们获得了多药耐药性。我们的研究结果表明,评估脑肿瘤中的GST-pi活性将为肿瘤的最终行为提供预测价值。